Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

Publications

Non-invasive tests for evaluation of liver disease severity and prognosis

Liver fibrosis is part of the structural and functional alterations in most chronic liver diseases.

It is one of the main prognostic factors as the amount of fibrosis is correlated with the risk of developing cirrhosis and liver-related complications in viral and non-viral chronic liver diseases [1,2]. Liver biopsy has traditionally been considered the reference method for evaluation of tissue damage such as hepatic fibrosis in patients with chronic liver disease. Pathologists have proposed robust scoring system for staging liver fibrosis such as the semi-quantitative METAVIR score [3,4].

Scroll to Top

Search EASL